Enrofloxacin (BAY-Vp2674, PD160788) is a fluoroquinolone antibiotic.
Enrofloxacin (BAY-Vp2674, PD160788) is a fluoroquinolone antibiotic.
Enrofloxacin is a synthetic chemotherapeutic agent from the class of the fluoroquinolone carboxylic acid derivatives. It has antibacterial activity against a broad spectrum of Gram-negative and Gram-positive bacteria. Enrofloxacin is believed to act by inhibiting bacterial DNA gyrase (a type-II topoisomerase), thereby preventing DNA supercoiling and DNA synthesis.
[1] Prescott JF, et al. Can J Vet Res, 1990, 54(1), 195-197. [2] Küng K, et al. J Vet Pharmacol Ther, 1993, 16(4), 462-468
Animal experiment: | Mice[2]11- to 14-week-old C57Bl6/J male mice are used. Enrofloxacin (2.5% oral solution) is dispensed in saline (2?mg/mL), antibiotic-treated animals receive a daily orally dispensed dose of 10?mg/kg body weight via feeding needle every 12 hours over a period of 7 days, while placebo animals receive the same amount of saline via feeding needle. Animals of preventive antibiotic group obtained Enrofloxacin after waking from reperfusion anesthesia (ca. 1 hour after operation). Therapeutic antibiotic treatment is given immediately after appearance of clinical signs (general health score>5) and confirmation of lung infection by MRI (signal rate≥5%). The group allocation is randomized[2]. |
参考文献: [1]. Sulyok KM, et al.Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central Europe. BMC Vet Res. 2014 Oct 25;10:256. | |
动态评分
0.0